<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086813</url>
  </required_header>
  <id_info>
    <org_study_id>D0510C00005</org_study_id>
    <secondary_id>AZD3043</secondary_id>
    <nct_id>NCT01086813</nct_id>
  </id_info>
  <brief_title>Phase I, Single Centre, Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043</brief_title>
  <acronym>AZD3043</acronym>
  <official_title>Phase I, Single Centre, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 After a Single Ascending Bolus Dose Followed by a Single Infusion Dose in Elderly (=65 Years) Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I, Single Centre, Open Label Study to Assess the Safety, Tolerability,Pharmacokinetics
      and Pharmacodynamics of Intravenous AZD3043 after aSingle Ascending Bolus Dose Followed by a
      Single Infusion Dose in Elderly(=65 years) Healthy Volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I, Single Centre, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics
      and Pharmacodynamics of Intravenous AZD3043 after a Single Ascending Bolus Dose Followed by a
      Single Infusion Dose in Elderly (=65 years) Healthy Volunteers
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The compound is being re-evaluated
  </why_stopped>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">April 2010</completion_date>
  <primary_completion_date type="Anticipated">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate safety and tolerability after administration of a bolus and infusion of AZD3043</measure>
    <time_frame>Heartrate, Bloodpressure, Telemetry, ECG, EtCO2, SPO2, BIS, Respiratory frequency every minute during a 1h session</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the PK of AZD3043 and its main metabolite (THRX-108893) in venous blood samples</measure>
    <time_frame>During 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the onset, level and recovery from sedation/anaesthesia</measure>
    <time_frame>During 24h</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Safety</condition>
  <condition>Tolerability</condition>
  <condition>Pharmacokinetics</condition>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3043</intervention_name>
    <description>single dose/IV, bolus over 60secs - infusion over 30 mins</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-anaesthesia assessment judged without remarks by the investigator.

          -  ASA physical status category 1 to 2 (up to and including 3 depending on applicable
             patient category)

        Exclusion Criteria:

          -  Lack of a normal range of enzyme activity for BuChE

          -  Known or suspected history of hypersensitivity to drugs with a similar chemical
             structure or class to AZD3043 (e.g., emulsion-based products like
             Diprivan,Intralipid), allergies to soybean or peanut products or any other drugs
             intended for use during th

          -  Prolonged QTcF &gt;450 ms or shortened QTcF &lt;350 ms or family history of long QT
             syndrome.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darren Wilbraham</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Drug Research Unit at Guy's HospitalQuintiles Ltd6 Newcomen StreetLondonSE1 1YRUnited Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Kanes</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brendan Smyth</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2010</study_first_submitted>
  <study_first_submitted_qc>March 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2010</study_first_posted>
  <last_update_submitted>December 19, 2012</last_update_submitted>
  <last_update_submitted_qc>December 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2012</last_update_posted>
  <responsible_party>
    <name_title>AstraZeneca</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Sedation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

